ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,738.17
-0.13%
Dow Jones
42,313.00
0.33%
US Dollar vs MXN
19.68869
0.33%
Brent Oil
71.905
1.35%
Bitcoin
65,669.25
0.75%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Entrada Therapeutics Inc (TRDA)

  7. Entrada Therapeutics Inc (TRDA) Noticias

TRDA

Entrada Therapeutics (TRDA)

Entrada Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TRDA
FechaHoraFuenteTítuloSímboloCompañía
24/09/202406:00GlobeNewswire Inc.Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and DevelopmentNASDAQ:TRDAEntrada Therapeutics Inc
10/09/202415:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
09/09/202415:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
06/09/202406:00GlobeNewswire Inc.Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant ProgramNASDAQ:TRDAEntrada Therapeutics Inc
13/08/202406:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TRDAEntrada Therapeutics Inc
13/08/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRDAEntrada Therapeutics Inc
13/08/202406:00GlobeNewswire Inc.Entrada Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
24/06/202406:15GlobeNewswire Inc.Entrada Therapeutics Announces $100 Million Registered Direct OfferingNASDAQ:TRDAEntrada Therapeutics Inc
24/06/202405:00GlobeNewswire Inc.Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
03/06/202406:00GlobeNewswire Inc.Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:TRDAEntrada Therapeutics Inc
16/05/202406:00GlobeNewswire Inc.Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:TRDAEntrada Therapeutics Inc
07/05/202406:00GlobeNewswire Inc.Entrada Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
13/03/202406:00GlobeNewswire Inc.Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
07/02/202406:00GlobeNewswire Inc.Entrada Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TRDAEntrada Therapeutics Inc
03/01/202406:00GlobeNewswire Inc.Entrada Therapeutics Promotes Nathan J. Dowden to PresidentNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202310:56Dow Jones NewsEntrada Therapeutics Shares Tumble 27% After FDA Keeps Clinical HoldNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202306:54Dow Jones NewsEntrada: FDA Declines to Lift Hold on Duchenne StudyNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202306:00GlobeNewswire Inc.Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
07/11/202306:00GlobeNewswire Inc.Entrada Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
29/09/202315:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TRDAEntrada Therapeutics Inc
21/09/202306:00GlobeNewswire Inc.Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
07/09/202306:00GlobeNewswire Inc.Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy CommunityNASDAQ:TRDAEntrada Therapeutics Inc
05/09/202315:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
10/08/202306:00GlobeNewswire Inc.Entrada Therapeutics Appoints Gina Chapman to its Board of DirectorsNASDAQ:TRDAEntrada Therapeutics Inc
08/08/202306:25Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TRDAEntrada Therapeutics Inc
08/08/202306:23Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:TRDAEntrada Therapeutics Inc
08/08/202306:00GlobeNewswire Inc.Entrada Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
01/08/202306:00GlobeNewswire Inc.Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
22/06/202315:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TRDAEntrada Therapeutics Inc
22/06/202315:13Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:TRDAEntrada Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TRDA

Su Consulta Reciente

USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
AMEX
XLV
Health Care Select Sector
NASDAQ
TSLA
Tesla
FX
EURUSD
Euro vs US Dollar
AMEX
XLF
Financial Select Sector
FX
EURMXN
Euro vs MXN
NASDAQ
QQQ
Invesco QQQ Trust Series 1
SPI
SP500
S&P 500
NASDAQ
MSFT
Microsoft
COIN
SOLUSD
Solana
PM
XAUUSD
Gold vs US Dollar
COIN
AVAXUSD
Avalanche
NYSE
BAC
Bank of America
CCOM
OILBRENT
Brent Oil
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados